BB Biotech AG / BB Biotech AG :Release of the Home Member State according to Article 2c of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

BB Biotech AG (ISIN CH0038389992) announces according to Art. 2c WpHG that Germany is the Home Member State. 

 

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch 

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Media release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB Biotech AG via Globenewswire
HUG#2022720

--- End of Message ---

BB Biotech AG
Schwertstrasse 6 Schaffhausen Switzerland

WKN: 888509;ISIN: CH0038389992;Index:HDAX,MIDCAP,TecDAX,TECH All Share,Prime All Share;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse;